Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements review discovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://rolimx430rlj4.wikiconversation.com/user